Verano Holdings (VRNO) Asset Writedowns and Impairment (2021 - 2025)

Verano Holdings' (VRNO) quarterly Asset Writedowns and Impairment came in at $177.4 million in Q4 2025, down 45.85% year-on-year from $327.7 million in Q4 2024, and up 3185.93% on a QoQ basis from $5.4 million in Q3 2025.

Verano Holdings (VRNO) Asset Writedowns and Impairment (2021 - 2025) Analysis & Trends

Verano Holdings (VRNO) has 5 years of Asset Writedowns and Impairment data on file, last reported at $177.4 million in Q4 2025.

  • On a quarterly basis, Asset Writedowns and Impairment fell 45.85% year-over-year to $177.4 million in Q4 2025; TTM through Dec 2025 was $511.0 million, a 55.87% increase from a year earlier, with the FY2025 full-year figure at $183.3 million, down 44.07% from the prior year.
  • Asset Writedowns and Impairment for Q4 2025 stood at $177.4 million, up from $5.4 million in the prior quarter.
  • Over the last five years, Asset Writedowns and Impairment for VRNO reached as high as $327.7 million in Q4 2024 and fell as low as -$2.2 million in Q4 2022.
  • Historically, Asset Writedowns and Impairment has averaged $43.1 million across 5 years, with a median of $510500.0 in 2023.
  • Across the five-year window, Asset Writedowns and Impairment sank 2468.24% in 2022 and retreated 12.02% in 2023, its largest moves.
  • Year by year, Asset Writedowns and Impairment stood at -$85000.0 in 2021, then slumped by 2468.24% to -$2.2 million in 2022, then soared by 401.01% to $6.6 million in 2023, then soared by 4887.05% to $327.7 million in 2024, then sank by 45.85% to $177.4 million in 2025.
  • Per Business Quant data, the three most recent Asset Writedowns and Impairment figures were $177.4 million in Q4 2025, $5.4 million in Q3 2025, and $428000.0 in Q2 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Haleon 89.28 Bn 87.42 Bn -
2 Teva Pharmaceutical Industries 35.97 Bn 32.23 Bn 1.97 Bn
3 Zoetis 32.42 Bn 30.48 Bn 1.62 Bn
4 Takeda Pharmaceutical 27.48 Bn 23.42 Bn 4.39 Bn
5 United Therapeutics 22.89 Bn 20.73 Bn 648.10 Mn
6 RedHill Biopharma 22.11 Bn 22.11 Bn -
7 Viatris 20.44 Bn 18.64 Bn 1.16 Bn
8 Neurocrine Biosciences 17.76 Bn 16.44 Bn 800.70 Mn
9 Elanco Animal Health 12.62 Bn 12.19 Bn 785.00 Mn
10 Verano Holdings 1.99 Bn 1.91 Bn 98.98 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 177.44 Mn
Dec 31, 2025 177.44 Mn
Sep 30, 2025 5.40 Mn
Sep 30, 2025 5.40 Mn
Jun 30, 2025 428,000.00
Jun 30, 2025 428,000.00
Dec 31, 2024 327.70 Mn
Dec 31, 2024 327.70 Mn
Mar 31, 2024 112,000.00
Mar 31, 2024 112,000.00
Sep 30, 2023 6.57 Mn
Sep 30, 2023 6.57 Mn
Mar 31, 2023 593,000.00
Mar 31, 2023 593,000.00
Dec 31, 2022 -2.18 Mn
Dec 31, 2022 -2.18 Mn
Jun 30, 2022 342,000.00
Jun 30, 2022 342,000.00
Mar 31, 2022 674,000.00
Mar 31, 2022 674,000.00